

Manhattan Pharmaceuticals Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

URL:	https://marketpublishers.com/r/M3AD3136A26BEN.html
Date:	December 15, 2017
Pages:	50
Price:	US\$ 499.00
ID:	M3AD3136A26BEN

Manhattan Pharmaceuticals Inc. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Manhattan Pharmaceuticals Inc. and its competitors. This provides our Clients with a clear understanding of Manhattan Pharmaceuticals Inc. position in the **Pharmaceuticals and Biotechnology Industry**.

- The report contains detailed information about Manhattan Pharmaceuticals Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Manhattan Pharmaceuticals Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.
- The Manhattan Pharmaceuticals Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.
- In the part that describes Manhattan Pharmaceuticals Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Manhattan Pharmaceuticals Inc. business.

About Manhattan Pharmaceuticals Inc.

Manhattan Pharmaceuticals, Inc., a development stage specialty healthcare product company, engages in the development and commercialization of treatments for underserved patient populations.

Products

Hedrin

Hedrin is a non-insecticide, one hour treatment for pediculosis (head lice) and is being developed in the United States as a prescription medical device. The company has a license agreement with Thornton & Ross Ltd. (T&R) and Kerris, S.A. (Kerris) for Hedrin. It also has a supply agreement with T&R pursuant to which T&R would be the company's supplier of Hedrin product.

The company entered into a joint venture agreement with Nordic Biotech Advisors ApS (Nordic) to develop and commercialize Hedrin for the North American market. The joint venture entity, H Pharmaceuticals (H Pharmaceuticals or the Hedrin JV), owns, is developing and is working to secure commercialization partners for Hedrin in both the United States and Canada.

AST-726

AST-726 is a nasally delivered form of hydroxocobalamin for the treatment of Vitamin B12 deficiency. The company has acquired global rights to AST-726 as part of the Ariston Pharmaceuticals, Inc. (Ariston) acquisition. AST-726 has demonstrated pharmacokinetic equivalence to a marketed intramuscular injection product for Vitamin B12 remediation. AST-726 has completed preclinical toxicology, and an investigational new drug (IND) application has been filed with the U.S. Food and Drug Administration (FDA).

AST-915

AST-915 is an orally delivered treatment for essential tremor. The company has acquired global rights to AST-915 as part of the Ariston acquisition. This product candidate is being studied under a cooperative research and development agreement (CRADA) with the National Institutes of Health (NIH) and a Phase 1 clinical study is underway in tremor patients.

Topical GEL for Psoriasis

The company is also developing a topical gel for the treatment of mild psoriasis Topical PTH (1-34) for the treatment of psoriasis. It owns global rights to this topical GEL and is exploring the possibility of developing it as an OTC product for mild psoriasis.

Discontinued Operations

In 2009, the company discontinued the research and development programs for Altoderm and Altolyn.

History

Manhattan Pharmaceuticals, Inc. was founded in 2001.

The above Company Fundamental Report is a half-ready report and contents are subject to change. It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Table of Content

RESEARCH METHODOLOGY

DISCLAIMER

1. MANHATTAN PHARMACEUTICALS INC. COMPANY PROFILE

1.1. Key facts

- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

2. MANHATTAN PHARMACEUTICALS INC. BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

3. MANHATTAN PHARMACEUTICALS INC. SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

4. MANHATTAN PHARMACEUTICALS INC. FINANCIAL ANALYSIS

- 4.1. Financial Statements
 - 4.1.1. Income Statement
 - 4.1.2. Balance Sheet
 - 4.1.3. Cash Flow
- 4.2. Financial Ratios
 - 4.2.1. Profitability
 - 4.2.2. Margin Analysis
 - 4.2.3. Asset Turnover
 - 4.2.4. Credit Ratios
 - 4.2.5. Long-Term Solvency
 - 4.2.6. Growth Over Prior Year
 - 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

5. MANHATTAN PHARMACEUTICALS INC. COMPETITORS AND INDUSTRY ANALYSIS

- 5.1. Manhattan Pharmaceuticals Inc. Direct Competitors
- 5.2. Comparison of Manhattan Pharmaceuticals Inc. and Direct Competitors Financial Ratios
- 5.3. Comparison of Manhattan Pharmaceuticals Inc. and Direct Competitors Stock Charts
- 5.4. Manhattan Pharmaceuticals Inc. Industry Analysis
 - 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
 - 5.4.2. Manhattan Pharmaceuticals Inc. Industry Position Analysis

6. MANHATTAN PHARMACEUTICALS INC. NEWS & EVENTS

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

7. MANHATTAN PHARMACEUTICALS INC. EXPERTS REVIEW¹

- 7.1. Experts Opinion

7.2. Experts Estimates

8. MANHATTAN PHARMACEUTICALS INC. ENHANCED SWOT ANALYSIS²

9. UNITED STATES PESTEL ANALYSIS²

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors

10. MANHATTAN PHARMACEUTICALS INC. IFE, EFE, IE MATRICES²

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

11. MANHATTAN PHARMACEUTICALS INC. PORTER FIVE FORCES ANALYSIS²

12. MANHATTAN PHARMACEUTICALS INC. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF TABLES

Manhattan Pharmaceuticals Inc. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Manhattan Pharmaceuticals Inc. Key Executives
Key Executives Biographies¹
Key Executives Compensations¹
Manhattan Pharmaceuticals Inc. Major Shareholders
Manhattan Pharmaceuticals Inc. History
Manhattan Pharmaceuticals Inc. Products
Revenues by Segment
Revenues by Region
Manhattan Pharmaceuticals Inc. Offices and Representations
Manhattan Pharmaceuticals Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Manhattan Pharmaceuticals Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios

Financial Ratios Growth Over Prior Year
Manhattan Pharmaceuticals Inc. Capital Market Snapshot
Manhattan Pharmaceuticals Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Manhattan Pharmaceuticals Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Manhattan Pharmaceuticals Inc. Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

LIST OF FIGURES

Manhattan Pharmaceuticals Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Manhattan Pharmaceuticals Inc. 1-year Stock Charts
Manhattan Pharmaceuticals Inc. 5-year Stock Charts
Manhattan Pharmaceuticals Inc. vs. Main Indexes 1-year Stock Chart
Manhattan Pharmaceuticals Inc. vs. Direct Competitors 1-year Stock Charts
Manhattan Pharmaceuticals Inc. Article Density Chart

1 – Data availability depends on company's security policy.

2 – These sections are available only when you purchase a report with appropriate additional types of analyses.

The complete financial data is available for publicly traded companies.

I would like to order:

Product name: Manhattan Pharmaceuticals Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Product link: <https://marketpublishers.com/r/M3AD3136A26BEN.html>
Product ID: M3AD3136A26BEN
Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/M3AD3136A26BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**